Literature DB >> 9627711

Differential regulation of integrins and extracellular matrix binding in epidermal differentiation and squamous tumor progression.

T Tennenbaum1, A J Belanger, V Quaranta, S H Yuspa.   

Abstract

Cell surface receptors of the integrin family regulate physiological and pathological processes in skin, including proliferation, differentiation, and malignant transformation. In skin, integrins are compartmentalized. While alpha 6 beta 4 is restricted to the basal surface of basal cells, beta 1 integrins are expressed in basal and suprabasal layers. In vivo and in Ca(2+)-induced differentiation of mouse keratinocytes in vitro, the loss of attachment to laminin via alpha 6 beta 4 integrin is an early event associated with initiation of spinous differentiation. The restricted expression of alpha 6 beta 4 to the basal cells in normal skin is disrupted early in the development of squamous cancer, where benign papillomas at high risk for malignant progression express alpha 6 beta 4 suprabasally in an expanded proliferative compartment. The aberrant suprabasal alpha 6 beta 4 is associated with reduced keratin 1 expression and upregulation of keratin 13, keratin 8, and gamma-glutamyltranspeptidase. During malignant conversion, the increase in alpha 6 beta 4 protein and mRNA is associated with novel expression of an alternatively spliced form of the alpha 6 subunit, alpha 6B. The induction of alpha 6B both in vivo and in vitro is particularly high in malignant cells produced by transduction of both v-fos and v-rasHa oncogenes into normal keratinocytes where it was associated with increased attachment to laminin. Furthermore, binding to laminin is increased by introduction of alpha 6B into a papilloma cell line. These results establish a link between squamous tumor progression and the upregulation of the alpha 6 beta 4 integrin and suggest that expression of alpha 6B could be functionally relevant to interaction of tumor cells with the laminin matrix during malignant conversion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9627711

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  5 in total

Review 1.  Laminin-332-integrin interaction: a target for cancer therapy?

Authors:  Daisuke Tsuruta; Hiromi Kobayashi; Hisayoshi Imanishi; Koji Sugawara; Masamitsu Ishii; Jonathan C R Jones
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 2.  Integrins in development and cancer.

Authors:  Luke R Anderson; Thomas W Owens; Matthew J Naylor
Journal:  Biophys Rev       Date:  2013-10-17

3.  Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis.

Authors:  Mary Ann Stepp; Sonali Pal-Ghosh; Gauri Tadvalkar; Lamise Rajjoub; Rosalyn A Jurjus; Michael Gerdes; Andrew Ryscavage; Christophe Cataisson; Anjali Shukla; Stuart H Yuspa
Journal:  Mol Carcinog       Date:  2010-04       Impact factor: 4.784

4.  Evidence of EGR1 as a differentially expressed gene among proliferative skin diseases.

Authors:  Min Fang; Sue Ann Wee; Karyn Ronski; Hongran Fan; Shiying Tao; Qun Lin
Journal:  Genomic Med       Date:  2007-07-25

5.  EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion.

Authors:  A Mariotti; P A Kedeshian; M Dans; A M Curatola; L Gagnoux-Palacios; F G Giancotti
Journal:  J Cell Biol       Date:  2001-10-29       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.